NVDA
RXRX
Bye-bye, backing
Nvidia just showed Recursion Pharmaceuticals the door. A recent 13F filing says the chip giant sold every last one of its 7.71 million shares, and RXRX did what stocks usually do when a high-profile investor heads for the exit: it fell hard.
The market heard “I’m out”
Recursion stock dropped roughly 12% after the disclosure, because markets are basically giant mood rings with Bloomberg terminals. The sale itself doesn’t come with an explanation, which means investors are left doing the usual spreadsheet detective work: Was this portfolio cleanup? A shift in AI priorities? Or just Nvidia cashing out?
Why you should care
When a megacap like Nvidia exits a position, it can matter even if the holding wasn’t huge relative to its own market cap. The bigger signal is psychological:
- a well-known strategic backer is gone
- speculative biotech names can reprice fast on sentiment alone
- traders may read it as a confidence check, fair or not
Big picture
This is a reminder that in market land, the story isn’t always the fundamentals — sometimes it’s who’s left holding the bag after the headline. And today, Recursion is the one wearing the very visible “sold” sign.